2019–2022 Sudanese transition to democracy

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 1, 2022
2019–2022 Sudanese transition to democracy, Eribulin, FDA, Research, Safety, EMBRACE, Senior, Breast cancer, Eisai, Pharmaceutical industry

TOKYO, Dec 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.

Key Points: 
  • TOKYO, Dec 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.
  • Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:
    - Real world use of eribulin following treatment with a P13K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.
  • - Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Victoria's Secret Launches Global Fund To Accelerate Innovation In Cancer Research For Women, By Women

Retrieved on: 
Tuesday, November 30, 2021
Patient, Fund, Caregiver, Cancer, 2019–2022 Sudanese transition to democracy, Workforce, AACR, Victoria's Secret, Secrecy, Population, NYSE, The Cancer Prevention and Treatment Fund, Diagnosis, Athleisure, MD, Woman, Breast, Cancer survivor, Program, Center, Female, Research, Communication, Tobacco Products Scientific Advisory Committee, American Association for Cancer Research, American Association, VSCO, Association, Pharmaceutical industry, Birth control

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Victoria's Secret and impact partner, Pelotonia , today announced the launch of the new Global Fund for Women's Cancers, established to accelerate innovation in cancer research for women, by women.

Key Points: 
  • NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Victoria's Secret and impact partner, Pelotonia , today announced the launch of the new Global Fund for Women's Cancers, established to accelerate innovation in cancer research for women, by women.
  • Nominations for these five meritorious awards will be accepted and reviewed by a committee of global cancer research experts overseen by The Fund's scientific partner, the American Association for Cancer Research (AACR) .
  • "We have long supported cancer research, but this particular program accelerating innovation in cancer research for women, by women is a tangible way we're supporting our brand's mission to create positive change for women."
  • The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer.